<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Snyder, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Cooper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 26, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with pituitary adenomas present with signs and symptoms of hormone hypersecretion (eg, hyperprolactinemia, growth hormone [GH] excess, or hypercortisolism). However, 25 to 35 percent of pituitary adenomas are clinically nonfunctioning or "silent"; 70 to 90 percent of these are gonadotroph adenomas, making them the most common type of pituitary macroadenoma. Patients with clinically nonfunctioning adenomas most often present with neurologic symptoms due to mass effects, while others may be completely asymptomatic and be first detected on an imaging study done for reasons other than pituitary symptoms or disease. By the time patients present, a high percentage have biochemical evidence of hypopituitarism due to compression of normal pituitary cells by the macroadenoma.
        </p>
        <p>
         The clinical features, evaluation, and diagnosis of clinically nonfunctioning pituitary adenomas are reviewed here. The treatment of these tumors and an overview of incidentally discovered sellar masses (pituitary incidentalomas) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">
          "Treatment of gonadotroph and other clinically nonfunctioning adenomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6642.html" rel="external">
          "Pituitary incidentalomas"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H96695262">
         <span class="h1">
          OVERVIEW OF PITUITARY ADENOMAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pituitary adenomas are classified by their cell of origin (lactotroph, gonadotroph, somatotroph, corticotroph, and thyrotroph) and their size (microadenomas &lt;1 cm, macroadenomas ≥1 cm). Most adenomas (65 to 70 percent) secrete an excess amount of hormone including prolactin, growth hormone (GH), corticotropin (ACTH), or thyroid-stimulating hormone (TSH). (See
         <a class="medical medical_review" href="/z/d/html/6626.html" rel="external">
          "Causes of hyperprolactinemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">
          "Causes and clinical manifestations of acromegaly"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/125.html" rel="external">
          "Causes and pathophysiology of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7842.html" rel="external">
          "TSH-secreting pituitary adenomas"
         </a>
         .)
        </p>
        <p>
         The remainder of pituitary adenomas (25 to 35 percent) are clinically nonfunctioning or "silent." Of these, 70 to 90 percent are gonadotroph adenomas [
         <a href="#rid1">
          1
         </a>
         ]. There are also clinically nonfunctioning somatotroph [
         <a href="#rid2">
          2,3
         </a>
         ], corticotroph, and lactotroph adenomas [
         <a href="#rid4">
          4
         </a>
         ], although these are less common.
        </p>
        <p>
         The majority of gonadotroph adenomas are clinically "silent" and difficult to identify because they are poorly differentiated and produce and secrete hormones inefficiently. The gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), consist of a common alpha subunit and a unique beta subunit. TSH and human chorionic gonadotropin (hCG) also consist of the common alpha subunit and a unique beta subunit. The hormones secreted by gonadotroph adenomas in order of decreasing frequency include: FSH, FSH-beta, alpha subunit, LH, and LH-beta [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Alpha subunit is not biologically active and also does not result in a clinical symptom due to its secretion. However, it is measured to evaluate patients with sellar masses to determine if the mass is pituitary in origin and whether there is accompanying hormonal hypersecretion. (See
         <a class="local">
          'Hormone excess'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H333975">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Estimates of the prevalence of pituitary adenomas are variable and are often based upon autopsy or magnetic resonance imaging (MRI) series. In a report from a single community of over 80,000 inhabitants in England, the prevalence of nonfunctioning pituitary adenomas (that had come to the attention of a clinician) was 22 per 100,000 [
         <a href="#rid6">
          6
         </a>
         ]. This is likely an underestimate of the true prevalence, as many nonfunctioning pituitary adenomas go undiagnosed until they are very large or are identified on an imaging study done for unrelated reasons.
        </p>
        <p>
         Gonadotroph adenomas are thought to be most common in men over age 50 years [
         <a href="#rid1">
          1
         </a>
         ] and less common in similar aged women, but this could be due to difficulty in recognizing gonadotroph adenomas in this population. High serum gonadotropins would be unlikely to raise suspicion for a gonadotroph adenoma in a woman over 50 years since she is likely to have elevated basal serum gonadotropin concentrations from the normal menopause [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7395.html" rel="external">
          "Clinical manifestations and diagnosis of menopause"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H291836653">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gonadotroph adenomas, like other pituitary adenomas, appear to be true clonal neoplasms [
         <a href="#rid8">
          8,9
         </a>
         ], but the mutations that cause them are not known. Genes that have been found to be overexpressed include the pituitary tumor transforming gene, Ki-67, and FGF-R [
         <a href="#rid10">
          10-12
         </a>
         ]. The maternally-expressed gene 3 (
         <em>
          MEG3
         </em>
         ) is underexpressed [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL PRESENTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonfunctioning pituitary adenomas (including the majority of gonadotroph adenomas) are difficult to recognize clinically until they are large enough to cause symptoms due to a mass effect. The three most common presentations include the following (
         <a class="graphic graphic_table graphicRef58084" href="/z/d/graphic/58084.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic symptoms – Most commonly, visual symptoms; less commonly, headache
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pituitary mass that is discovered as an incidental finding when an imaging procedure is done for reasons other than pituitary symptoms or disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pituitary hypofunction due to compression of normal pituitary tissue by the adenoma
        </p>
        <p>
        </p>
        <p>
         Less commonly, patients with gonadotroph adenomas may present with clinical syndromes due to hypersecretion of follicle-stimulating hormone (FSH) or, rarely, luteinizing hormone (LH; ovarian hyperstimulation or precocious puberty). (See
         <a class="local">
          'Hormone excess'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Neurologic symptoms
         </span>
        </p>
        <p class="headingAnchor" id="H177771361">
         <span class="h3">
          Visual impairment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Impaired vision, caused by suprasellar extension of the adenoma that compresses the optic chiasm, is the most common symptom that leads a patient with a gonadotroph or other clinically nonfunctioning adenoma to seek medical attention (
         <a class="graphic graphic_diagnosticimage graphicRef87693" href="/z/d/graphic/87693.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid14">
          14-16
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common type of vision impairment is visual field loss, typically diminished vision in the temporal fields (superior temporal quadrantanopsia or temporal hemianopsia). One or both eyes may be affected. In a review of eight series of 1719 patients with clinically nonfunctioning pituitary adenomas, visual field disturbances were present in 798 (46 percent) [
         <a href="#rid14">
          14
         </a>
         ], while in a single-center series of 295 patients, the frequency was even higher (192 of 295, 65 percent) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diminished visual acuity, which occurs when the optic chiasm is more severely compressed [
         <a href="#rid16">
          16
         </a>
         ], was reported in approximately 30 percent of patients in one series [
         <a href="#rid15">
          15
         </a>
         ]. Thus, an intrasellar lesion should be suspected when there is any unexplained pattern of visual loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The onset of visual deficits is usually so gradual that many patients do not seek ophthalmologic consultation for months or even years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diplopia, induced by oculomotor nerve compression resulting from lateral extension of the adenoma, may occur, but it is less common, occurring in up to 10 to 15 percent of patients in several large series [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H177771368">
         <span class="h3">
          Headache
         </span>
         <span class="headingEndMark">
          —
         </span>
         Headaches, the second most common neurologic symptom, occur in 30 to 40 percent of patients [
         <a href="#rid14">
          14,15
         </a>
         ] and are thought to be due to sellar expansion. There is no distinguishing characteristic of the headaches, although they are usually diffuse.
        </p>
        <p class="headingAnchor" id="H177771375">
         <span class="h3">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other less common neurologic symptoms include [
         <a href="#rid16">
          16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebrospinal fluid rhinorrhea, caused by inferior extension of the adenoma, rarely occurs spontaneously [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pituitary apoplexy (sudden hemorrhage into a pituitary macroadenoma), is also rare. It causes excruciating headache and visual impairment [
         <a href="#rid18">
          18
         </a>
         ]. This may occur spontaneously but has also been reported during pregnancy, surgery, and with anticoagulant use [
         <a href="#rid19">
          19
         </a>
         ]. It has been described less commonly after thyrotropin-releasing hormone (TRH) and gonadotropin-releasing hormone (GnRH) stimulation tests [
         <a href="#rid20">
          20,21
         </a>
         ] and with gonadotropin-releasing hormone (GnRH) agonist therapy for prostate cancer [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Incidental finding on imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         The common use of magnetic resonance imaging (MRI) to evaluate symptoms in the head or neck has resulted in the incidental discovery of many intrasellar lesions. In two MRI series of 100 [
         <a href="#rid24">
          24
         </a>
         ] and 52 [
         <a href="#rid25">
          25
         </a>
         ] normal volunteers, 10 (10 percent) and 25 (38 percent), respectively, had previously unsuspected sellar lesions, but almost all were &lt;10 mm. However, in one review of eight series of pituitary "incidentalomas" discovered on MRI, 68 percent were macroadenomas [
         <a href="#rid14">
          14
         </a>
         ]. This percentage is much higher than other imaging series, suggesting that patients likely had symptoms suggestive of a sellar mass that led to the imaging study.
        </p>
        <p>
         The evaluation and management of these adenomas are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6642.html" rel="external">
          "Pituitary incidentalomas"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Symptoms due to hormonal abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically nonfunctioning adenomas often present with evidence of hypopituitarism (usually biochemical). On rare occasions, gonadotroph adenomas present with hormonal hypersecretion causing a clinical syndrome such as ovarian hyperstimulation or precocious puberty.
        </p>
        <p>
         Gonadotroph adenomas, like all other types of pituitary adenomas, can occur as part of the multiple endocrine neoplasia type 1 (MEN1) syndrome, a rare heritable disorder classically characterized by a predisposition to tumors of the parathyroid glands, anterior pituitary, and pancreatic islet cells. (See
         <a class="medical medical_review" href="/z/d/html/2037.html" rel="external">
          "Multiple endocrine neoplasia type 1: Genetics", section on 'MEN1 gene'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H280094">
         <span class="h3">
          Hormone deficiencies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who present with neurologic symptoms, when carefully questioned, may acknowledge symptoms of pituitary hormone deficiencies that are due to compression of nonadenomatous cells by the macroadenoma. However, these symptoms tend to be nonspecific (fatigue and lethargy) and are not usually the reason that the patient seeks medical attention.
        </p>
        <p>
         The most common clinical hormone deficiency is impaired secretion of gonadotropins resulting in hypogonadism. In a series of 295 patients with nonfunctioning pituitary adenomas, 61 of 161 men (38 percent) had low serum gonadotropins, resulting in low serum testosterone, decreased libido, and erectile dysfunction [
         <a href="#rid15">
          15
         </a>
         ]. In the same report, 33 percent of the women of reproductive age had menstrual cycle disorders.
        </p>
        <p>
         Higher percentages of hypopituitarism may be detected biochemically in patients with clinically nonfunctioning adenomas. In a review of eight series of 1719 patients, 993 (58 percent) had laboratory evidence of pituitary hormone deficiency [
         <a href="#rid14">
          14
         </a>
         ]. The most common pituitary hormone deficiencies were:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Growth hormone (GH) (87 percent, 220 of 252 tested). Testing for GH deficiency was less common in older series because GH deficiency was not thought to have important clinical consequences. (See
         <a class="medical medical_review" href="/z/d/html/6641.html" rel="external">
          "Growth hormone deficiency in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LH/FSH (hypogonadotropic hypogonadism; 1216 of 1699 patients tested, 72 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Corticotropin (ACTH) (secondary adrenal insufficiency; 514 of 1699, 30 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid-stimulating hormone (TSH) (central hypothyroidism; 402 of 1699, 24 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H333794">
         <span class="h3">
          Hormone excess
         </span>
        </p>
        <p class="headingAnchor" id="H3848112393">
         <span class="h4">
          Gonadotroph adenomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although gonadotroph adenomas are considered to be "nonfunctioning," most do produce intact gonadotropins or their subunits. However, these adenomas are typically poorly differentiated and inefficient producers/secretors and do not raise serum gonadotropin concentrations. Thus, they are usually clinically "silent" and cannot be distinguished from other clinically nonfunctioning adenomas until immunohistochemistry is performed after pituitary surgery.
        </p>
        <p>
         However, approximately 35 percent of gonadotroph adenomas secrete enough LH or FSH to raise serum gonadotropin levels [
         <a href="#rid26">
          26
         </a>
         ], but clinical syndromes due to hypersecretion of intact gonadotropins are rare. However, several syndromes have been recognized (
         <a class="graphic graphic_table graphicRef74280" href="/z/d/graphic/74280.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid27">
          27
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ovarian hyperstimulation has been reported in premenopausal women [
         <a href="#rid28">
          28-34
         </a>
         ] and, rarely, in prepubertal girls [
         <a href="#rid35">
          35,36
         </a>
         ]. The slight, but persistently, elevated serum FSH concentrations lead to recruitment of multiple dominant follicles, high serum estradiol (E2) concentrations (&gt;500 pg/mL), and thickened endometrium on pelvic ultrasound (potentially suggestive of endometrial hyperplasia). The clinical picture is similar to ovarian stimulation with exogenous FSH when administered for fertility treatment (
         <a class="graphic graphic_diagnosticimage graphicRef77302" href="/z/d/graphic/77302.html" rel="external">
          image 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because the multiple follicles are not triggered to ovulate, women present with amenorrhea or oligomenorrhea [
         <a href="#rid28">
          28-34
         </a>
         ], and prepubertal girls present with breast development, vaginal bleeding, and abdominal distension [
         <a href="#rid35">
          35,36
         </a>
         ]. If pituitary surgery is successful in removing the adenoma but not removing the normal pituitary, gonadotropin secretion and ovarian function returns to normal [
         <a href="#rid33">
          33,37-40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An LH-secreting pituitary adenoma resulting in precocious puberty has been reported in two boys [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The majority of gonadotroph adenomas that secrete intact gonadotropins occur in middle-aged adults and do
         <strong>
          not
         </strong>
         result in a clinical syndrome. In postmenopausal women, for example, a gonadotroph adenoma that secretes intact gonadotropins would not result in a clinical syndrome, because gonadotropin levels are already high and a postmenopausal ovary cannot be stimulated to produce follicles or E2. However, in males, elevated serum testosterone concentration due to hypersecretion of intact LH and testicular enlargement due to FSH hypersecretion have been described [
         <a href="#rid5">
          5,43,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13631672">
         <span class="h4">
          Other pituitary adenomas
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Somatotroph adenomas
         </strong>
         – In 100 consecutive patients with pituitary adenomas that were surgically excised, 24 had somatotroph adenomas by immunochemical staining [
         <a href="#rid3">
          3
         </a>
         ]. Of these, eight (one-third) had an elevated insulin-like growth factor 1 (IGF-1) concentration but not even subtle manifestations of acromegaly and could therefore be considered to be clinically silent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Corticotroph adenomas
         </strong>
         – Clinically silent corticotroph adenomas might be recognizable by higher plasma ACTH concentrations than other macroadenomas [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H406942372">
         <span class="h3">
          Elevated prolactin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Macroadenomas often compress the pituitary stalk and obstruct the normal inhibitory hypothalamic influence on the prolactin-producing cells, resulting in modestly elevated serum prolactin concentrations (usually &lt;100 ng/mL but sometimes as high as 200 ng/mL). Illustrated in one study of 226 patients with nonfunctioning macroadenomas, a serum prolactin concentration &gt;94 ng/mL reliably distinguished between lactotroph adenomas and nonfunctioning adenomas [
         <a href="#rid45">
          45
         </a>
         ]. Rarely, gonadotroph adenomas cosecrete prolactin and gonadotropins.
        </p>
        <p class="headingAnchor" id="H280057">
         <span class="h2">
          Characteristic imaging features
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted, gonadotroph adenomas are generally hormonally inefficient; as a result, by the time a gonadotroph adenoma produces supranormal serum concentrations of intact gonadotropins or their subunits, it is a macroadenoma (&gt;1 cm) by imaging (
         <a class="graphic graphic_diagnosticimage graphicRef87693" href="/z/d/graphic/87693.html" rel="external">
          image 1
         </a>
         ). MRI in a patient with neurologic symptoms usually shows a large intrasellar mass that is frequently extending outside of the sella. Elevation of the optic chiasm or extension into the cavernous sinuses or sphenoid sinus can also be detected. MRI with gadolinium is preferred to computed tomography (CT) because it provides superior resolution of the mass and its relation to surrounding structures. (See
         <a class="local">
          'Pituitary imaging'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">
          "Causes, presentation, and evaluation of sellar masses", section on 'MRI'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3066201354">
         <span class="h2">
          Aggressive pituitary adenomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although most pituitary adenomas are benign and follow an indolent course, some are aggressive and partially or entirely resistant to all forms of treatment. A meta-analysis found that 31 percent of clinically silent corticotroph adenomas recurred, a similar frequency as other kinds of clinically silent adenomas. The management of some types of aggressive pituitary adenomas is discussed separately [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">
          "Treatment of gonadotroph and other clinically nonfunctioning adenomas", section on 'Aggressive tumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H280339">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the patient whose presenting signs, symptoms, or prior imaging suggests a sellar mass includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Take a detailed history and perform a physical examination, recognizing that any visual abnormalities or other neurologic symptoms could represent a sellar mass. The history should also focus on possible symptoms of hypopituitarism, including symptoms of hypogonadism in men (fatigue, decreased libido, erectile dysfunction) and women (amenorrhea/oligomenorrhea). (See
         <a class="local">
          'Neurologic symptoms'
         </a>
         above and
         <a class="local">
          'Hormone deficiencies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Confirm the presence of a sellar mass by a magnetic resonance imaging (MRI) dedicated to this region, if not already done. If a sellar mass is confirmed, assess its size, relationship to chiasm, and cavernous sinuses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visual field and visual acuity testing. (See
         <a class="local">
          'Visual field testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biochemical testing to detect other kinds of pituitary adenomas by their excessive hormonal secretion (eg, lactotroph, somatotroph, and, less commonly, corticotroph adenomas). (See
         <a class="local">
          'Hormone excess'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biochemical testing for excessive secretion of gonadotropins and their subunits, as they are characteristic of gonadotroph adenomas. This includes measurement of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), and alpha subunit concentrations. (See
         <a class="local">
          'Hormone excess'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biochemical testing also for pituitary hypofunction due to compression of normal pituitary cells by the adenoma. (See
         <a class="local">
          'Hormonal testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         We agree with the Endocrine Society Clinical Practice Guidelines on Pituitary Incidentaloma and suggest MRI, visual field testing, and biochemical evaluation for hormone hypersecretion and hypopituitarism for patients with pituitary incidentalomas that are &gt;1 cm in size [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6642.html" rel="external">
          "Pituitary incidentalomas"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Pituitary imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest MRI for the initial imaging study for suspected adenomas because of its superior resolution and its ability to demonstrate the optic chiasm. MRI with gadolinium is preferred to computed tomography (CT) because it provides superior resolution of the mass and its relation to surrounding structures. MRI is also able to detect blood, thereby permitting recognition of hemorrhage into the pituitary and distinction of an aneurysm from other intrasellar lesions (
         <a class="graphic graphic_diagnosticimage graphicRef87693" href="/z/d/graphic/87693.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
         However, MRI will not distinguish adenomatous tissue from normal pituitary tissue. MRI will also not distinguish a gonadotroph adenoma from other pituitary macroadenomas and often not even from nonpituitary lesions. This topic is reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">
          "Causes, presentation, and evaluation of sellar masses", section on 'MRI'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H335448">
         <span class="h2">
          Visual field testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with sellar masses &gt;1 cm or elevating the optic chiasm, including those who deny visual symptoms, should undergo baseline Humphrey visual field testing and evaluation of visual acuity. A clinician experienced in evaluating visual field abnormalities, such as a neuro-ophthalmologist, should interpret the results.
        </p>
        <p class="headingAnchor" id="H334287526">
         <span class="h2">
          Hormonal testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypothalamic-pituitary hormonal function (both hyper- and hypofunction) should be evaluated whenever a large sellar mass (&gt;1 cm) is seen on MRI to determine if it is a pituitary adenoma that can be recognized by hormonal hypersecretion.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypersecretion -
         </strong>
         The possibility of hormone excess should be evaluated to detect the presence of functioning pituitary adenomas. We therefore suggest measurements of:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum LH, FSH, and alpha subunit (gonadotroph adenoma). In countries where thyrotropin-releasing hormone (TRH) is available, the FSH and alpha subunit response to TRH will also identify a gonadotroph adenoma (
         <a class="graphic graphic_table graphicRef74280" href="/z/d/graphic/74280.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum prolactin (lactotroph adenomas).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Insulin-like growth factor 1 (IGF-1) (somatotroph adenomas).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Plasma ACTH, 24-hour urine free cortisol (corticotroph adenomas).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypopituitarism -
         </strong>
         Deficient secretion of other pituitary hormones often occurs due to the mass effect of the typically large gonadotroph adenomas and should always be investigated. Additional testing for hormone deficiencies due to compression of the normal pituitary tissue includes measurement of the serum concentrations of:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         8 AM cortisol
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thyroxine (T4) (if elevated, measure thyroid-stimulating hormone [TSH] to evaluate the possibility of a thyrotroph adenoma)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Testosterone in men
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Estradiol (E2) in women of premenopausal age with amenorrhea
        </p>
        <p>
        </p>
        <p>
         The interpretation of pituitary tests and the diagnosis of hypopituitarism are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">
          "Diagnostic testing for hypopituitarism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H593746940">
         <span class="h3">
          Gonadotroph adenomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         In postmenopausal women, a sellar mass can be recognized as a gonadotroph adenoma biochemically by the combination of an elevated FSH and/or alpha subunit and a suppressed LH (
         <a class="graphic graphic_table graphicRef74280" href="/z/d/graphic/74280.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Alpha subunit values should be interpreted in the context of normal values for the specific patient group and specific assay. The serum concentration of uncombined alpha subunit is elevated in women in three physiologic conditions [
         <a href="#rid48">
          48-50
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Menopause, in which the gonadotroph cells of the pituitary hypersecrete intact FSH and LH and uncombined alpha subunit
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy, in which the placenta secretes intact human chorionic gonadotropin (hCG) and uncombined alpha subunit
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ovarian stimulation with exogenous gonadotropins (hCG,
         <a class="drug drug_general" data-topicid="9607" href="/z/d/drug information/9607.html" rel="external">
          human menopausal gonadotropins
         </a>
         [hMG], FSH) for the treatment of infertility
        </p>
        <p>
        </p>
        <p>
         In men, a sellar mass can be recognized as a gonadotroph adenoma by a supranormal basal serum FSH concentration (
         <a class="graphic graphic_figure graphicRef52535" href="/z/d/graphic/52535.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid51">
          51
         </a>
         ]. An elevated concentration of alpha subunit indicates a gonadotroph adenoma, thyrotroph adenoma, or less differentiated glycoprotein adenoma. A supranormal response of intact FSH or alpha subunit to TRH also indicates a gonadotroph adenoma.
        </p>
        <p>
         Finding evidence for a gonadotroph adenoma will not influence the choice of therapy (which is pituitary surgery), but recognizing that a sellar mass is a gonadotroph adenoma and not a nonpituitary lesion could influence the route of surgery and can be used as a tumor marker by which to evaluate the result of surgery and for subsequent monitoring. Finding evidence for one of the other types of clinically nonfunctioning adenomas could also open the possibility of pharmacologic treatment. (See
         <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">
          "Treatment of gonadotroph and other clinically nonfunctioning adenomas"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2860385294">
         <span class="h3">
          Somatotroph adenomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although somatotroph adenomas typically cause the characteristic clinical syndrome of acromegaly, some are silent. They can result in excessive hormonal secretion without even the subtlest clinical change ("clinically silent") or no clinical or biochemical evidence of excessive hormonal secretion ("totally silent"). In 100 consecutive patients with pituitary adenomas that were surgically excised, 24 had somatotroph adenomas by immunochemical staining [
         <a href="#rid3">
          3
         </a>
         ]. Of these, eight (one-third) had an elevated IGF-1 concentration but not even subtle manifestations of acromegaly and could therefore be considered to be clinically silent.
        </p>
        <p class="headingAnchor" id="H3590798806">
         <span class="h3">
          Corticotroph adenomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Corticotroph macroadenomas, unlike microadenomas, do not typically cause Cushing syndrome. However, they may be clinically silent and recognizable by elevated plasma corticotropin (ACTH) concentrations [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1839965099">
         <span class="h3">
          Lactotroph adenomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most lactotroph macroadenomas produce very high serum prolactin concentrations, but some are inefficient and do not. These may be difficult to distinguish from other sellar lesions that compress the pituitary stalk and obstruct the normal inhibitory hypothalamic influence on the prolactin producing cells, resulting in modestly elevated serum prolactin concentrations (usually &lt;100 ng/mL but sometimes as high as 200 ng/mL). Illustrated in one study of 226 patients with nonfunctioning macroadenomas, a serum prolactin concentration &gt;94 ng/mL reliably distinguished between lactotroph adenomas and nonfunctioning adenomas [
         <a href="#rid45">
          45
         </a>
         ]. Rarely, gonadotroph adenomas cosecrete prolactin and gonadotropins.
        </p>
        <p class="headingAnchor" id="H263258">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A definitive diagnosis of a gonadotroph adenoma is made by pathologic evaluation of the excised tissue. Pituitary adenomas typically show effacement of the normal lobular pituitary architecture and instead show a monomorphic population of cells and loss of the normal reticulin pattern. Immunochemical staining may be positive for follicle-stimulating hormone (FSH)-beta, luteinizing hormone (LH)-beta, and/or alpha subunit. Even more likely is positive immunostaining for steroidogenic factor 1 (SF-1), the transcription factor responsible for the final differentiation of the gonadotroph cell [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         However, the diagnosis of a gonadotroph adenoma can be made with a reasonable degree of certainty preoperatively in a patient with a large sellar mass in the following circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum prolactin concentration less than 100 ng/mL. (See
         <a class="local">
          'Elevated prolactin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No symptoms or signs of acromegaly and serum concentration of insulin-like growth factor 1 (IGF-1) not elevated. (See
         <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">
          "Causes and clinical manifestations of acromegaly"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6635.html" rel="external">
          "Diagnosis of acromegaly"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No signs or symptoms of Cushing syndrome and 24-hour urine cortisol excretion not elevated. (See
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In men, elevated basal serum concentrations of intact FSH and/or of alpha subunit (
         <a class="graphic graphic_table graphicRef74280" href="/z/d/graphic/74280.html" rel="external">
          table 2
         </a>
         ). In countries where thyrotropin-releasing hormone (TRH) is available, an FSH response to TRH. Rarely, elevated LH and testosterone. Elevated FSH and LH and subnormal testosterone indicate primary hypogonadism. (See
         <a class="local">
          'Primary hypogonadism'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In premenopausal women, irregular menses, elevated FSH and estradiol (E2), low LH, and on pelvic ultrasound, massive polycystic ovaries and thickened endometrium.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In postmenopausal women, elevated FSH and/or alpha subunit and low LH (
         <a class="graphic graphic_table graphicRef74280" href="/z/d/graphic/74280.html" rel="external">
          table 2
         </a>
         ). Elevation of both FSH and LH likely indicate only normal postmenopausal gonadotropin secretion.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pituitary adenomas are the most common cause of a large sellar mass, but other causes include craniopharyngioma, meningioma, malignant tumors, Rathke's cleft cysts, and hypophysitis. Any sellar masses &gt;1 cm may present with neurologic symptoms similar to clinically nonfunctioning pituitary adenomas. Evaluation of a large sellar mass includes imaging with magnetic resonance imaging (MRI), and hormonal evaluation for pituitary hyper- and hypofunction. (See
         <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">
          "Causes, presentation, and evaluation of sellar masses", section on 'Evaluation of a sellar mass'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6642.html" rel="external">
          "Pituitary incidentalomas", section on 'Lesions 10 mm or larger'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H96694932">
         <span class="h2">
          Lactotroph macroadenoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, a large sellar mass associated with a prolactin concentration &lt;100 ng/mL probably does not represent a lactotroph adenoma. Large sellar masses compress the pituitary stalk and thereby prevent dopamine from the hypothalamus from reaching the pituitary, thus decreasing normal inhibition of prolactin secretion. The result is a mild elevation of serum prolactin (&gt;20 ng/mL [eg, higher than normal] but usually &lt;100 ng/mL) [
         <a href="#rid45">
          45,53
         </a>
         ]. (See
         <a class="local">
          'Elevated prolactin'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6638.html" rel="external">
          "Clinical manifestations and evaluation of hyperprolactinemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H96694952">
         <span class="h2">
          Primary hypogonadism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Longstanding primary hypogonadism can cause gonadotroph cell hypertrophy and therefore overall pituitary enlargement [
         <a href="#rid54">
          54,55
         </a>
         ] and, in this way, as well as in elevated gonadotropin concentrations, is similar to gonadotroph adenomas. Primary hypogonadism differs from gonadotroph adenomas in several ways:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The degree of pituitary enlargement is much less
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are elevated
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neither intact gonadotropins nor their subunits respond to thyrotropin-releasing hormone (TRH) [
         <a href="#rid51">
          51,56
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H406941432">
         <span class="h2">
          Polycystic ovary syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with polycystic ovary syndrome (PCOS) have multiple follicles on pelvic ultrasound. However, they are small and arranged in a peripheral pattern, unlike the follicles described in the cases of ovarian hyperstimulation syndrome in women with gonadotroph adenomas (
         <a class="graphic graphic_diagnosticimage graphicRef77302" href="/z/d/graphic/77302.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid28">
          28-34
         </a>
         ]. In addition, serum FSH concentrations are low in PCOS, not normal or high as they would be with a gonadotroph adenoma. Lastly, a serum estradiol (E2) concentration &gt;500 pg/mL should strongly raise the suspicion that the multiple ovarian cysts are due to a gonadotroph adenoma (
         <a class="graphic graphic_diagnosticimage graphicRef77302" href="/z/d/graphic/77302.html" rel="external">
          image 2
         </a>
         ) rather than PCOS.
        </p>
        <p class="headingAnchor" id="H1099140064">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116762.html" rel="external">
          "Society guideline links: Pituitary tumors and hypopituitarism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H744403">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/82820.html" rel="external">
          "Patient education: Pituitary adenoma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1218774792">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence of nonfunctioning adenomas
         </strong>
         – Approximately 25 to 35 percent of all pituitary adenomas are clinically nonfunctioning or "silent"; 70 to 90 percent of these are gonadotroph adenomas. (See
         <a class="local">
          'Overview of pituitary adenomas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Clinically nonfunctioning adenomas (including gonadotroph adenomas) usually come to clinical attention when they become large enough to cause neurologic symptoms such as impaired vision (diminished vision in the temporal fields [bitemporal hemianopsia] and diminished visual acuity), and nonspecific headaches, (See
         <a class="local">
          'Neurologic symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some are detected as an incidental finding when magnetic resonance imaging (MRI) is done for other reasons. (See
         <a class="local">
          'Incidental finding on imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Approximately 60 percent of patients at the time of diagnosis have hypopituitarism due to compression by the macroadenoma. Hormonal deficiencies are usually not the presenting symptoms. (See
         <a class="local">
          'Symptoms due to hormonal abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gonadotroph adenomas are difficult to recognize because they secrete variably and inefficiently, and often do not cause a clinical syndrome. (See
         <a class="local">
          'Hormone excess'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Evaluation of the patient who presents with neurologic symptoms suggestive of a clinically nonfunctioning sellar mass should first include pituitary MRI. If a sellar mass &gt;1 cm is detected on pituitary MRI, the following should be performed (see
         <a class="local">
          'Evaluation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Visual field testing
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Biochemical testing for hypersecretion of other pituitary hormones (serum prolactin, insulin-like growth factor 1 [IGF-1], and 24-hour urine free cortisol) (see
         <a class="local">
          'Hormone excess'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Biochemical testing for gonadotropins and their subunit (follicle-stimulating hormone [FSH], luteinizing hormone [LH] and alpha subunit)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Testing for hypopituitarism – 8 AM cortisol, thyroxine (T4), testosterone in men and estradiol (E2) in women of premenopausal age (see
         <a class="local">
          'Hormonal testing'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         –
         <strong>
         </strong>
         The diagnosis of a gonadotroph adenoma is likely if there is a large sellar mass, no clinical or biochemical evidence of acromegaly or Cushing syndrome, the serum prolactin is &lt;100 ng/mL, and the concentrations of gonadotropins are characteristic (
         <a class="graphic graphic_table graphicRef74280" href="/z/d/graphic/74280.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Chaidarun SS, Klibanski A. Gonadotropinomas. Semin Reprod Med 2002; 20:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakharova AA, Dimaraki EV, Chandler WF, Barkan AL. Clinically silent somatotropinomas may be biochemically active. J Clin Endocrinol Metab 2005; 90:2117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wade AN, Baccon J, Grady MS, et al. Clinically silent somatotroph adenomas are common. Eur J Endocrinol 2011; 165:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ioachimescu AG, Eiland L, Chhabra VS, et al. Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas. Neurosurgery 2012; 71:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamoun R, Layfield L, Couldwell WT. Gonadotroph adenoma with secondary hypersecretion of testosterone. World Neurosurg 2013; 80:900.e7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daneshdoost L, Gennarelli TA, Bashey HM, et al. Recognition of gonadotroph adenomas in women. N Engl J Med 1991; 324:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander JM, Biller BM, Bikkal H, et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990; 86:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herman V, Fagin J, Gonsky R, et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990; 71:1427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999; 84:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 2007; 28:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramírez C, Cheng S, Vargas G, et al. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 2012; 97:1745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gejman R, Batista DL, Zhong Y, et al. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2008; 93:4119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 2008; 37:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrante E, Ferraroni M, Castrignanò T, et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 2006; 155:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snyder PJ. Gonadotroph cell adenomas of the pituitary. Endocr Rev 1985; 6:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam G, Mehta V, Zada G. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature. Neurosurg Focus 2012; 32:E2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nawar RN, AbdelMannan D, Selman WR, Arafah BM. Pituitary tumor apoplexy: a review. J Intensive Care Med 2008; 23:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semple PL, Jane JA Jr, Laws ER Jr. Clinical relevance of precipitating factors in pituitary apoplexy. Neurosurgery 2007; 61:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szabolcs I, Késmárki N, Bor K, et al. Apoplexy of a pituitary macroadenoma as a severe complication of preoperative thyrotropin-releasing hormone (TRH) testing. Exp Clin Endocrinol Diabetes 1997; 105:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frankart L, De Hertogh R, Donckier J, et al. [Pituitary apoplexy of a gonadotrophinoma and TRH/GnRH tests. Literature review]. Acta Clin Belg 1995; 50:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massoud W, Paparel P, Lopez JG, et al. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer. Int J Urol 2006; 13:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerra Y, Lacuesta E, Marquez F, et al. Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Pituitary 2010; 13:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong BW, Kucharczyk W, Singer W, George S. Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas. AJNR Am J Neuroradiol 1994; 15:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho DM, Hsu CY, Ting LT, Chiang H. The clinicopathological characteristics of gonadotroph cell adenoma: a study of 118 cases. Hum Pathol 1997; 28:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ntali G, Capatina C, Grossman A, Karavitaki N. Clinical review: Functioning gonadotroph adenomas. J Clin Endocrinol Metab 2014; 99:4423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djerassi A, Coutifaris C, West VA, et al. Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation. J Clin Endocrinol Metab 1995; 80:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christin-Maitre S, Rongières-Bertrand C, Kottler ML, et al. A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma. J Clin Endocrinol Metab 1998; 83:3450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Välimäki MJ, Tiitinen A, Alfthan H, et al. Ovarian hyperstimulation caused by gonadotroph adenoma secreting follicle-stimulating hormone in 28-year-old woman. J Clin Endocrinol Metab 1999; 84:4204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pentz-Vidovíc I, Skorić T, Grubisić G, et al. Evolution of clinical symptoms in a young woman with a recurrent gonadotroph adenoma causing ovarian hyperstimulation. Eur J Endocrinol 2000; 143:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimon I, Rubinek T, Bar-Hava I, et al. Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 2001; 86:3635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castelbaum AJ, Bigdeli H, Post KD, et al. Exacerbation of ovarian hyperstimulation by leuprolide reveals a gonadotroph adenoma. Fertil Steril 2002; 78:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murata Y, Ando H, Nagasaka T, et al. Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. J Clin Endocrinol Metab 2003; 88:1988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashiro H, Katabuchi H, Ohtake H, et al. A follicle-stimulating hormone-secreting gonadotroph adenoma with ovarian enlargement in a 10-year-old girl. Fertil Steril 1999; 72:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gryngarten MG, Braslavsky D, Ballerini MG, et al. Spontaneous ovarian hyperstimulation syndrome caused by a follicle-stimulating hormone-secreting pituitary macroadenoma in an early pubertal girl. Horm Res Paediatr 2010; 73:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murakami T, Higashitsuji H, Yoshinaga K, et al. Management of ovarian hyperstimulation due to follicle-stimulating hormone-secreting gonadotroph adenoma. BJOG 2004; 111:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugita T, Seki K, Nagai Y, et al. Successful pregnancy and delivery after removal of gonadotrope adenoma secreting follicle-stimulating hormone in a 29-year-old amenorrheic woman. Gynecol Obstet Invest 2005; 59:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts JE, Spandorfer S, Fasouliotis SJ, et al. Spontaneous ovarian hyperstimulation caused by a follicle-stimulating hormone-secreting pituitary adenoma. Fertil Steril 2005; 83:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mor E, Rodi IA, Bayrak A, et al. Diagnosis of pituitary gonadotroph adenomas in reproductive-aged women. Fertil Steril 2005; 84:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faggiano M, Criscuolo T, Perrone L, et al. Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma. Acta Endocrinol (Copenh) 1983; 102:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrosi B, Bassetti M, Ferrario R, et al. Precocious puberty in a boy with a PRL-, LH- and FSH-secreting pituitary tumour: hormonal and immunocytochemical studies. Acta Endocrinol (Copenh) 1990; 122:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snyder PJ, Sterling FH. Hypersecretion of LH and FSH by a pituitary adenoma. J Clin Endocrinol Metab 1976; 42:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahlqvist P, Koskinen LO, Brännström T, Hägg E. Testicular enlargement in a patient with a FSH-secreting pituitary adenoma. Endocrine 2010; 37:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karavitaki N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 2006; 65:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fountas A, Lavrentaki A, Subramanian A, et al. Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis. J Clin Endocrinol Metab 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papapetrou PD, Anagnostopoulos NI. A gonadotropin and alpha-subunit suppression test for the assessment of the ectopic production of human chorionic gonadotropin and its subunits after the menopause. J Clin Endocrinol Metab 1985; 60:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glinoer D, De Nayer P, Robyn C, et al. Serum levels of intact human chorionic gonadotropin (HCG) and its free alpha and beta subunits, in relation to maternal thyroid stimulation during normal pregnancy. J Endocrinol Invest 1993; 16:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unkila-Kallio L, Tiitinen A, Alfthan H, et al. Effect of an in vitro fertilization program on serum CA 125, tumor-associated trypsin inhibitor, free beta-subunit of human chorionic gonadotropin, and common alpha-subunit of glycoprotein hormones. Fertil Steril 2000; 74:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daneshdoost L, Gennarelli TA, Bashey HM, et al. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone. J Clin Endocrinol Metab 1993; 77:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and Pathological Aspects of Silent Pituitary Adenomas. J Clin Endocrinol Metab 2019; 104:2473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen KA, Tho SP, Gomez F, McDonough PG. Nonfunctioning pituitary macroadenoma presenting with mild hyperprolactinemia and amenorrhea. Fertil Steril 1999; 72:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dadachanji MC, Bharucha NE, Jhankaria BG. Pituitary hyperplasia mimicking pituitary tumor. Surg Neurol 1994; 42:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samaan NA, Stepanas AV, Danziger J, Trujillo J. Reactive pituitary abnormalities in patients with Klinefelter's and Turner's syndromes. Arch Intern Med 1979; 139:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snyder PJ, Bashey HM, Kim SU, Chappel SC. Secretion of uncombined subunits of luteinizing hormone by gonadotroph cell adenomas. J Clin Endocrinol Metab 1984; 59:1169.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6627 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12536357" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Gonadotropinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15671111" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinically silent somatotropinomas may be biochemically active.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21493729" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinically silent somatotroph adenomas are common.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22517250" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23201183" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Gonadotroph adenoma with secondary hypersecretion of testosterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19650784" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1899470" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Recognition of gonadotroph adenomas in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1973174" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinically nonfunctioning pituitary tumors are monoclonal in origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1977759" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clonal origin of pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10022450" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325339" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pituitary tumor-transforming gene: physiology and implications for tumorigenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22419713" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18628527" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18226735" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Nonfunctioning pituitary tumors and pituitary incidentalomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17132751" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2416559" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Gonadotroph cell adenomas of the pituitary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22655691" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18372348" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pituitary tumor apoplexy: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18091272" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clinical relevance of precipitating factors in pituitary apoplexy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9285212" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Apoplexy of a pituitary macroadenoma as a severe complication of preoperative thyrotropin-releasing hormone (TRH) testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7631532" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : [Pituitary apoplexy of a gonadotrophinoma and TRH/GnRH tests. Literature review].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16448441" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19842040" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8154641" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8010269" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9269826" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The clinicopathological characteristics of gonadotroph cell adenoma: a study of 118 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25166722" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical review: Functioning gonadotroph adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7852525" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9768644" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10566673" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Ovarian hyperstimulation caused by gonadotroph adenoma secreting follicle-stimulating hormone in 28-year-old woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11078984" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Evolution of clinical symptoms in a young woman with a recurrent gonadotroph adenoma causing ovarian hyperstimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502789" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12477530" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Exacerbation of ovarian hyperstimulation by leuprolide reveals a gonadotroph adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12727942" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10428166" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A follicle-stimulating hormone-secreting gonadotroph adenoma with ovarian enlargement in a 10-year-old girl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20215777" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Spontaneous ovarian hyperstimulation syndrome caused by a follicle-stimulating hormone-secreting pituitary macroadenoma in an early pubertal girl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15521879" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Management of ovarian hyperstimulation due to follicle-stimulating hormone-secreting gonadotroph adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15637432" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Successful pregnancy and delivery after removal of gonadotrope adenoma secreting follicle-stimulating hormone in a 29-year-old amenorrheic woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15652911" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Spontaneous ovarian hyperstimulation caused by a follicle-stimulating hormone-secreting pituitary adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16169418" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Diagnosis of pituitary gonadotroph adenomas in reproductive-aged women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6681924" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2112813" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Precocious puberty in a boy with a PRL-, LH- and FSH-secreting pituitary tumour: hormonal and immunocytochemical studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/767353" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Hypersecretion of LH and FSH by a pituitary adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20960265" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Testicular enlargement in a patient with a FSH-secreting pituitary adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16984247" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30590584" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21474686" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Pituitary incidentaloma: an endocrine society clinical practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3923023" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A gonadotropin and alpha-subunit suppression test for the assessment of the ectopic production of human chorionic gonadotropin and its subunits after the menopause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7511622" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Serum levels of intact human chorionic gonadotropin (HCG) and its free alpha and beta subunits, in relation to maternal thyroid stimulation during normal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11119738" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Effect of an in vitro fertilization program on serum CA 125, tumor-associated trypsin inhibitor, free beta-subunit of human chorionic gonadotropin, and common alpha-subunit of glycoprotein hormones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8077332" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30020466" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinical and Pathological Aspects of Silent Pituitary Adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10521106" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Nonfunctioning pituitary macroadenoma presenting with mild hyperprolactinemia and amenorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7974144" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Pituitary hyperplasia mimicking pituitary tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/434974" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Reactive pituitary abnormalities in patients with Klinefelter's and Turner's syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6436288" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Secretion of uncombined subunits of luteinizing hormone by gonadotroph cell adenomas.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
